Stock SUNESIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Sunesis Pharmaceuticals, Inc. Nasdaq

Equities

US8673286014

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Reverse Split: 1 of 3.5
FA
SUNESIS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Sunesis Pharmaceuticals, Inc. Announces Executive Changes
CI
SUNESIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Sunesis Pharmaceuticals, Inc.(NasdaqCM:SNSS) dropped from NASDAQ Composite Index
CI
Viracta Therapeutics, Inc. completed the acquisition of Sunesis Pharmaceuticals, Inc. for approximately $100 million in a reverse merger transaction.
CI
SUNESIS PHARMACEUTICALS : Oppenheimer Upgrades Sunesis Pharmaceuticals to Outperform from Perform, Sets $12 Price Target
MT
SUNESIS PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
SUNESIS PHARMACEUTICALS INC : Other Events (form 8-K)
AQ
SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS
BU
SUNESIS PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form 8-K)
AQ
Sunesis Pharmaceuticals, Inc. Announces Board Changes
CI
Sunesis Pharmaceuticals, Inc. Announces Executive Changes
CI
Sunesis Pharmaceuticals, Inc. Announces Executive Changes
CI
SUNESIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS
BU
Sunesis Pharmaceuticals : to Combine with Viracta Therapeutics in All-Stock Deal
MT
Transcript : Sunesis Pharmaceuticals, Inc., Viracta Therapeutics, Inc. - M&A Call
SUNESIS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. Stock
  5. News Sunesis Pharmaceuticals, Inc.